Continued Response to One Dose of Nivolumab Complicated by Myasthenic Crisis and Myositis

J Thorac Oncol. 2017 Jul;12(7):e90-e91. doi: 10.1016/j.jtho.2017.02.024.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antineoplastic Agents, Immunological / adverse effects*
  • Humans
  • Male
  • Middle Aged
  • Myasthenia Gravis / etiology*
  • Myasthenia Gravis / pathology
  • Myositis / etiology*
  • Myositis / pathology
  • Nivolumab / adverse effects*

Substances

  • Antineoplastic Agents, Immunological
  • Nivolumab